GSK Registers A Win For Older People RSV Vaccine – But Awaited Data Will Be Crucial
Prevention Rate Still Undisclosed
GSK has declared success for its RSV vaccine and will begin regulatory talks immediately – but the final efficacy level, as yet unrevealed, could be decisive in a competitive market.
You may also be interested in...
Strong RSV Vaccine Results Gives GSK An Edge Over Rival Pfizer
GSK looks to have established an efficacy edge over its rivals in developing a vaccine against the respiratory syncytial virus, but analysts expect early 2023 approvals to spark a closely fought contest.
Pfizer’s RSV Vaccine Shows Efficacy In Older Adults, Setting Up Showdown With GSK
Pfizer’s bivalent vaccine candidate showed efficacy in RSV patients with multiple respiratory infection symptoms and may offer protection against the A and B strains of the virus.
Barron Signs Off With Notes On GSK Culture Change, Tease On RSV Vaccine Results
Hal Barron is leaving just as GSK’s M&A firepower grows following the Haleon spin-out, but sounded a confident note about its potential blockbuster RSV vaccine candidate.